文献速递前列腺癌男科与性医学

药物去势对高血糖雄性ApoE-/-:Ins2+/Akita小鼠代谢紊乱和心血管疾病的保护作用

Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-09-28

本研究在高血糖ApoE-/-:Ins2+/Akita小鼠模型中比较三种雄激素剥夺治疗(ADT)方式对代谢和心血管的影响。结果显示药物去势改善糖代谢异常和动脉粥样硬化负担,GnRH拮抗剂组生存期最长,其次为睾丸切除术。

要点

  • 药物去势可改善高血糖小鼠的糖代谢异常和动脉粥样硬化负担。
  • GnRH拮抗剂组体重增加更少,瘦素水平和收缩压更低。
  • GnRH拮抗剂组生存期优于GnRH激动剂组,但与睾丸切除术组无差异。

核心结论

  • 药物性ADT可改善ApoE-/-:Ins2+/Akita小鼠的代谢综合征和心血管并发症。
  • 糖代谢异常和动脉粥样硬化的改善与生存期延长相关,GnRH拮抗剂组生存期最长,其次为睾丸切除术。

研究设计与样本

  • 雄性ApoE-/-:Ins2+/Akita小鼠接受三种ADT方式之一(GnRH拮抗剂地加瑞克、GnRH激动剂亮丙瑞林或双侧睾丸切除术),并与未治疗对照组比较,每组n=9-13。
  • 小鼠随访5个月,检测体重、空腹血糖、糖耐量、血清C肽、瘦素、睾酮水平及动脉粥样硬化斑块大小和特征;另设独立实验评估生存期。

主要发现

  • 三种ADT方式均实现去势。
  • 地加瑞克组体重增加显著少于睾丸切除组和亮丙瑞林组,血清瘦素水平和收缩压更低。
  • ADT改善糖代谢异常和动脉粥样硬化负担。
  • GnRH拮抗剂组生存期显著优于GnRH激动剂组,但与睾丸切除术组相比无显著差异。

临床怎么用

  • 在高血糖合并心血管风险的男性中,药物去势可能对代谢和心血管有保护作用。
  • GnRH拮抗剂可能较GnRH激动剂带来更优的生存获益,但需结合临床情况选择。

局限性

  • 研究为动物模型,结果不能直接外推至人类。
  • 样本量较小(每组n=9-13)。
  • 未报告具体数值和统计比较的P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, a population with high prevalence of cardiovascular disease and its risk factors. Our objectives were to test and further characterize the effects of pharmacological castration which is currently the acceptable modality to deliver ADT in the clinic. METHODS: Male ApoE-/-:Ins2+/Akita mice received one of three modes of ADT (gonadotropin-releasing hormone (GnRH)-antagonist (degarelix), GnRH-agonist (leuprolide), or bilateral orchiectomy) and were compared to corresponding untreated control mice (n = 9-13/group). Mice were followed for 5 months. Body weight, fasting blood glucose, glucose tolerance, serum C-peptide, leptin, and testosterone levels along with atherosclerotic aortic plaque size and characteristics were determined. In a separate experiment, the survival of mice, untreated and on ADT, was determined. RESULTS: Castration was achieved for all three modes of ADT. However, degarelix-treated mice gained significantly less weight, had lower serum leptin levels and systolic blood pressure compared to orchiectomy and leuprolide-treated mice. ADT improved dysglycemia and atherosclerotic burden. GnRH-antagonist significantly improved survival compared to GnRH-agonist but not compared to orchiectomy. CONCLUSIONS: Further characterization of the ApoE-/-:Ins2+/Akita mouse model confirms that pharmacological ADT ameliorated metabolic syndrome and cardiovascular complications. Improved dysglycemia and atherosclerosis associated with increased survival which was longest after degarelix followed by orchiectomy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Duivenvoorden WCM, Naeim M, Hopmans SN, et al. Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model. Prostate Cancer Prostatic Dis. 2020. PMID: 32989260. doi:10.1038/s41391-020-00288-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。